7,580.07

-140.32

-1.82%

51,770.30

-572.30

-1.09%

25,437.00

-747.73

-2.86%

2,811.84

-47.37

-1.66%

4.9290

-0.0600

-1.20%

19.42

+2.22

+12.91%

3,884.90

-146.50

-3.63%

77,185.28

-831.67

-1.07%

Crude Oil Dec 26

102.95

+0.95

+0.93%

US Private Equity

10,850.63

-82.20

-0.75%

OTC Markets OTCPK - Delayed Quote USD

WuXi Biologics (Cayman) Inc. (WXIBF)

5.90 0.00 (0.00%)

At close: October 29 at 4:00:00 PM EDT

Loading Chart for WXIBF

Chart Range Bar

Interval:

In partnership with ChartIQ

WuXi Biologics Receives Top-Honor Jade Award at The Asset Corporate Sustainability Leadership Awards 2026

WuXi Biologics Receives Top-Honor Jade Award at The Asset Corporate Sustainability Leadership Awards 2026

Can WuXi Biologics (Cayman) (SEHK:2269) Stay Reasonable As Capacity Expands?

Can WuXi Biologics (Cayman) (SEHK:2269) Stay Reasonable As Capacity Expands?

WuXi Biologics Continues to Be Included in Multiple Hang Seng Sustainability Indexes, Demonstrating ESG Excellence

WuXi Biologics Continues to Be Included in Multiple Hang Seng Sustainability Indexes, Demonstrating ESG Excellence

Recombinant Proteins Manufacturing Services Market Report Released; 19.7% CAGR as revenue nearly triples from $5.2B to $15.3B by 2030; benchmark WuXi Biologics, GenScript, Bio-Rad, ACROBiosystems and Syngene amid tariff disruption

Recombinant Proteins Manufacturing Services Market Report Released; 19.7% CAGR as revenue nearly triples from $5.2B to $15.3B by 2030; benchmark WuXi Biologics, GenScript, Bio-Rad, ACROBiosystems and Syngene amid tariff disruption

WuXi Biologics Passes Another FDA GMP Inspection, Reinforcing Its Quality Track Record and Commercial Supply Reliability

WuXi Biologics Passes Another FDA GMP Inspection, Reinforcing Its Quality Track Record and Commercial Supply Reliability

WuXi Biologics Named to Forbes China ESG 50 List 2026 for Green CRDMO and Digital ESG Leadership

WuXi Biologics Named to Forbes China ESG 50 List 2026 for Green CRDMO and Digital ESG Leadership

Big Pharma Is Pouring Billions Into China’s Biotechs

Big Pharma Is Pouring Billions Into China’s Biotechs

WuXi Biologics Reports Strong Profitable Growth in H1 2026

WuXi Biologics Reports Strong Profitable Growth in H1 2026

WuXi Biologics Recognized for Industry Top Sustainable Biopharma Practices Empowering the Industry's Transformation Through Green CRDMO

WuXi Biologics Recognized for Industry Top Sustainable Biopharma Practices Empowering the Industry's Transformation Through Green CRDMO

Vertex Autoimmune Deal With WuXi Adds New Angle To VRTX Valuation Story

Vertex Autoimmune Deal With WuXi Adds New Angle To VRTX Valuation Story

Vertex Partners With WuXi To Broaden Autoimmune Pipeline Beyond Cystic Fibrosis

Vertex Partners With WuXi To Broaden Autoimmune Pipeline Beyond Cystic Fibrosis

Mobilize your Website

View Site in Mobile | Classic

Share by: